Last reviewed · How we verify

Olumacostat Glasaretil Gel, 5.0% — Competitive Intelligence Brief

Olumacostat Glasaretil Gel, 5.0% (Olumacostat Glasaretil Gel, 5.0%) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: SOAT1 inhibitor. Area: Dermatology.

phase 3 SOAT1 inhibitor SOAT1 (sterol O-acyltransferase 1) Dermatology Small molecule Live · refreshed every 30 min

Target snapshot

Olumacostat Glasaretil Gel, 5.0% (Olumacostat Glasaretil Gel, 5.0%) — Dermira, Inc.. Olumacostat glasaretil inhibits sebum production by blocking sterol O-acyltransferase (SOAT1), reducing lipid accumulation in sebaceous glands.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Olumacostat Glasaretil Gel, 5.0% TARGET Olumacostat Glasaretil Gel, 5.0% Dermira, Inc. phase 3 SOAT1 inhibitor SOAT1 (sterol O-acyltransferase 1)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (SOAT1 inhibitor class)

  1. Dermira, Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Olumacostat Glasaretil Gel, 5.0% — Competitive Intelligence Brief. https://druglandscape.com/ci/olumacostat-glasaretil-gel-5-0. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators: